4:31 pm Gilead Sciences announces Phase 1 data for investigational therapy, GS-6615, in patients with long QT-3 syndrome
View todays social media effects on GILD
View the latest stocks trending across Twitter. Click to view dashboard
See who Gilead is hiring next, click here to view
